BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32012432)

  • 1. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
    Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
    Musser ML; Johannes CM
    BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
    Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
    Musser ML; Taikowski KL; Johannes CM; Bergman PJ
    BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
    Merino-Gutierrez V; Borrego JF; Puig J; Hernández A; Clemente-Vicario F
    J Small Anim Pract; 2021 Oct; 62(10):881-885. PubMed ID: 34131916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
    Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
    Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
    Kim C; Matsuyama A; Mutsaers AJ; Woods JP
    Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
    Flesner BK; Fletcher JM; Smithee T; Boudreaux B
    J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.